Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyroid hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: Thyroid hormone. Displaying page 9 of 12.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    EudraCT Number: 2006-002704-34 Sponsor Protocol Number: HGS1008-C1067 Start Date*: 2007-04-27
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P...
    Medical condition: Chronic Hepatitis C (CHC) genotype 2/3.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) SE (Completed) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002703-13 Sponsor Protocol Number: HGS1008-C1060 Start Date*: 2007-03-20
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P...
    Medical condition: Chronic hepatitis C (CHC) genotype 1.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001220-20 Sponsor Protocol Number: P03833 Start Date*: 2005-01-25
    Sponsor Name:Integrated Therapeutics Group, Incorporated - a subsidiary of Schering-Plough
    Full Title: Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys
    Medical condition: Chronic Hepatitis C, Genotype 1
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019777-15 Sponsor Protocol Number: GLP114130 Start Date*: 2010-09-10
    Sponsor Name:GlaxoSmithKline LLC
    Full Title: A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Me...
    Medical condition: Type 2 Diabetes Mellitus With Renal Impairment
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019497-32 Sponsor Protocol Number: PGL09-027 Start Date*: 2010-11-09
    Sponsor Name:PregLem S.A.
    Full Title: A Phase III, multicentre, clinical study investigating the efficacy and safety of three successive periods of 3-month open-label PGL4001 treatment, each followed by ten days of double-blind treatme...
    Medical condition: Uterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly as...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) PL (Completed) AT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003151-20 Sponsor Protocol Number: 8931-017 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer?s Disease. (Phase 2/3; Protocol No. MK-8931-017-02) ...
    Medical condition: mild to moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) PT (Completed) HU (Completed) BE (Completed) AT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005206-37 Sponsor Protocol Number: CNTO136MDD2001 Start Date*: 2015-09-14
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    19.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004220-30 Sponsor Protocol Number: BA058-05-019 Start Date*: 2018-07-25
    Sponsor Name:Radius Health, Inc.
    Full Title: A Randomized, Double blind, Placebo controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide SC for the Treatment of Men with Osteoporosis.
    Medical condition: Osteoporosis in men
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000688-57 Sponsor Protocol Number: AROAPOC3-2002 Start Date*: 2021-11-10
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003489-42 Sponsor Protocol Number: 31-12-294 Start Date*: 2013-03-12
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
    Medical condition: Tics associated with Tourette’s Disorder in children and adolescents
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) ES (Prematurely Ended) IT (Completed) DE (Ongoing) SE (Completed) NL (Ongoing) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003063-21 Sponsor Protocol Number: HLX10-005-SCLC301 Start Date*: 2020-06-17
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Randomized, Double-Blind, Multicenter, Phase III Study to Compare Clinical Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemoth...
    Medical condition: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002916-16 Sponsor Protocol Number: CSOM230B2219 Start Date*: 2014-08-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s ...
    Medical condition: Cushing's disease and acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10011651 Cushing's disease LLT
    19.0 100000004860 10000600 Acromegaly and gigantism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-007030-35 Sponsor Protocol Number: CLBH589B2206 Start Date*: 2007-11-15
    Sponsor Name:NOVARTIS FARMA
    Full Title: A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 when administered in combination with oral lenalidomide & dexamethasone in adult patients with multiple myeloma
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006638-16 Sponsor Protocol Number: CLBH589B2207 Start Date*: 2007-07-17
    Sponsor Name:NOVARTIS FARMA
    Full Title: A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 and IV bortezomib in adult patients with multiple myeloma
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022513-26 Sponsor Protocol Number: SKY1052-2-001 Start Date*: 2011-02-22
    Sponsor Name:SkyePharma AG
    Full Title: Randomised, single-blind, placebo controlled, four-period four-treatment cross-over design, proof of concept study to compare the pharmacodynamic, safety and pharmacokinetics of one single administ...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012601 Diabetes mellitus LLT
    12.1 10012608 Diabetes mellitus insulin-dependent LLT
    12.1 10012610 Diabetes mellitus loss of control LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000931-15 Sponsor Protocol Number: ICR-CTSU/2016/10060 Start Date*: 2018-07-02
    Sponsor Name:Institute of Cancer Research
    Full Title: PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer.
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-003820-40 Sponsor Protocol Number: D1050231 Start Date*: 2008-03-17
    Sponsor Name:Dainippon Sumitomo Pharma America, Inc.
    Full Title: A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019773-15 Sponsor Protocol Number: CLI-107-14 Start Date*: 2010-07-20
    Sponsor Name:CYTHERIS
    Full Title: A multicenter, open-labeled, controlled, randomized study of recombinant Interleukin-7 (CYT107) treatment to restore and maintain CD4 T-lymphocyte counts above 500 cells/�L in HIV-infected patients...
    Medical condition: HIV infected patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003623-37 Sponsor Protocol Number: CAN-PDP Start Date*: 2020-02-12
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: CANnabidiol for Parkinson’s Disease Psychosis
    Medical condition: Parkinson's disease psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10074835 Parkinson's disease psychosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000899-23 Sponsor Protocol Number: CORT125134-451 Start Date*: 2016-08-16
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 26 02:18:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA